Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.

@article{Lai2016ModularPD,
  title={Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.},
  author={Ashton C. Lai and Momar Toure and Doris Hellerschmied and Jemilat Salami and Saul Jaime-Figueroa and Eunhwa Ko and John Hines and Craig M. Crews},
  journal={Angewandte Chemie},
  year={2016},
  volume={55 2},
  pages={
          807-10
        }
}
Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs. PROTAC technology employs small molecules that recruit target proteins for ubiquitination and removal by the proteasome. The synthesis of PROTAC compounds that mediate the degradation of c-ABL and BCR-ABL by recruiting either Cereblon or Von Hippel Lindau E3 ligases is reported. During… Expand
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
TLDR
A previously understudied benefit of small molecule proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degradation is reported. Expand
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
TLDR
A detail summary on the latest one year progress of PROTAC target various proteins and elucidate the advantages of PROTac technology are provided. Expand
Proteolysis targeting chimeras (PROTACs) in cancer therapy
TLDR
The molecular medicine behind PROTAC mechanism of action is discussed, with special emphasis on recent developments and their potential translation to the clinical setting. Expand
Assays and technologies for developing proteolysis targeting chimera degraders
Targeted protein degradation by small-molecule degraders represents an emerging mode of action in drug discovery. Proteolysis targeting chimeras (PROTACs) are small molecules that can recruit an E3Expand
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
TLDR
The potential of PROTACs to become anticancer therapeutics, chemical and bioinformatics approaches for PROTAC design, and safety concerns are discussed with a special focus on the development of tumor-specific/selectiveprotACs. Expand
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
TLDR
The ability to target receptor tyrosine kinases for degradation using the PROTAC technology is demonstrated and the advantages of this degradation-based approach are outlined. Expand
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
TLDR
This review systematically summarizes the known PROTACs that have the potential to be used to treat various hematologic malignancies and proposes to use the latest human pan-tissue single-cell RNA sequencing data to identify hematopoietic cell type-specific/selective E3 ligases to generate tumor-specific/. Expand
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
TLDR
The biological mechanism, advantages and recent progress of PROTACs are summarized, trying to offer an outlook in development of drugs targeting degradation in future. Expand
Degradation of proteins by PROTACs and other strategies
TLDR
Recent meaningful research of PROTAC is summarized, including the types of degradation proteins, preliminary biological data in vitro and in vivo, and new E3 ubiquitin ligases, which strongly proved the value of the PROTAC strategy. Expand
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
TLDR
This review will present the most relevant progresses made, especially in the last two years, in the application of PROTACs technology to the three main classes of e-POIs: "writers", "erasers" and "readers". Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
TLDR
This work has generated the first small molecule targeting the von Hippel–Lindau protein, the substrate recognition subunit of an E3 ligase, and an important target in cancer, chronic anemia, and ischemia, and obtained the crystal structure of VHL bound to the most potent inhibitor. Expand
Phthalimide conjugation as a strategy for in vivo target protein degradation
TLDR
A chemical strategy that promotes ligand-dependent target protein degradation using as an example the transcriptional coactivator BRD4, a protein critical for cancer cell growth and survival is devised. Expand
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
TLDR
It is shown that MetAP-2 can be tethered to SCFβ-TRCP, ubiquitinated, and degraded in a Protac-1-dependent manner, which may be useful for conditional inactivation of proteins, and for targeting disease-causing proteins for destruction. Expand
Catalytic in vivo protein knockdown by small-molecule PROTACs.
TLDR
Major improvements to the proteolysis targeting chimeras (PROTACs) method are described, a chemical knockdown strategy in which a heterobifunctional molecule recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degradation. Expand
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
TLDR
ARV-825 is designed, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation ofBRD4 in all BL cell lines tested. Expand
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
TLDR
Proteolysis Targeted Chimeras (PROTACs) that tether JQ1 to a ligand for the E3 ubiquitin ligase VHL, aimed at triggering the intracellular destruction of BET proteins open up new opportunities to elucidate the cellular phenotypes and therapeutic implications associated with selective targeting of BRD4. Expand
Development of target protein-selective degradation inducer for protein knockdown.
TLDR
An amide-type SNIPER is synthesized and biologically evaluated which induces selective degradation of cellular retinoic acid binding protein II (CRABP-II), but not IAPs. Expand
Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.
TLDR
Novel small-molecule inhibitors of the interaction between VHL and its molecular target HIF1α, a transcription factor involved in oxygen sensing are reported. Expand
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia. Small moleculeExpand
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
TLDR
Analysis of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of d asatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL. Expand
...
1
2
3
...